S
Suzhou Deyun Kangrui Biotechnology
Biophysical analysis of molecular interactions via nanotechnology
About Suzhou Deyun Kangrui Biotechnology
Dynamic Biosystems is a German company specializing in the development and marketing of biosensors for the analysis of molecular interactions. The company's core technology, switchSENSE®, is a biophysical research tool used to investigate interactions between molecules in real-time. This technology is based on DNA nanolevers attached to gold microelectrodes on a chip surface. By applying an alternating voltage, the DNA nanolevers are made to oscillate, and the system measures changes in fluorescence intensity to provide data on binding kinetics, affinity, and the conformational changes of binding partners. This allows for a detailed, multiparameter characterization of biomolecules from a single measurement.
Read full description
The company offers a biosensor platform with device series such as the heliX, heliX+, and heliXcyto. The heliX line utilizes the switchSENSE® technology for measuring molecule-molecule interactions. In 2023, the firm introduced Real-Time Interaction Cytometry (RT-IC) with its heliXcyto biosensor, which enables the measurement of molecular interactions directly on the surface of single cells immobilized in micro-cages. This product aims to bridge the gap between traditional biosensor technology and cytometry. The technology serves researchers in basic research, drug discovery, and cell and gene therapy development. The team consists of over 60 life science specialists located in Munich, Germany, and Woburn, MA, in the United States. Suzhou Deyun Kangrui Biotechnology Co., Ltd., established in June 2020, appears to be the Chinese entity related to Dynamic Biosystems' operations, holding numerous patents in the region.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Suzhou Deyun Kangrui Biotechnology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2023 | $14M | $89M | Guan Ya Investment · Ruihua Capital · Longpan Investment | ↗ |
| SERIES A✓Equity / VC | Nov 2021 | $18M | $72M | Lin Changqing · Rongsheng Venture Capital · Rejing Bio · Hillhouse Capital | — |
Growth signals
Latest recorded traffic for Suzhou Deyun Kangrui Biotechnology is 20 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 BioSenicFor autoimmune, inflammatory and bone diseases |
Mont-Saint-Guibert, Belgium | Operational | 16 | $9M | $32M |
 RenovacorTransformative Therapies for Cardiovascular Disease |
Narberth, United States | Acquired | |||
 Latch MedicalA new approach to drug and vaccine delivery |
Dublin, Ireland | Operational | |||
 DrugBankAI-powered pharmaceutical knowledge platform for drug development |
Edmonton, Canada | Operational | |||
 PredxBioTissue-Based Decision Intelligence for Oncology |
Bellevue, United States | Operational | |||
 SymbiomicsHigh-performance agricultural biologicals using microbiome and genomic technologies |
Florianópolis, Brazil | Operational | |||
 ZyVersa TherapeuticsA clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs |
Weston, United States | Operational | |||
 Vasa TherapeuticsPrecision medicine for heart failure and healthy aging |
Encinitas, United States | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Proxima Ventures
Series A8 investors entered at this stage
Hillhouse Capital
HM Capital- LCLin Changqing
- RCRongsheng Venture Capital
- RBRejing Bio
- LILongpan Investment
- GIGuan Ya Investment
- RCRuihua Capital
Other known investors1 additional known investor
Xiamen University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Deyun Kangrui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Deyun Kangrui Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.